| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.004 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.15 | 0.005 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.099 | 0.005 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.081 | 0.005 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.12 | 0.005 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.006 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.094 | 0.007 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.007 |